Core Insights - A new company, Jinhe Aichongyi (Shanghai) Biotechnology Co., Ltd., has been established with a registered capital of 10 million yuan [1] - The company's business scope includes medical research and experimental development, cell technology research and application, and internet information services for pharmaceuticals [1] - Jinhe Aichongyi is wholly owned by Jinhe Biology (002688) [1]

天眼查App显示，近日，黑龙江粒粒壮生物技术有限公司成立，法定代表人为俞柯伟，注册资本666万 人民币，经营范围为一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；生 态环境材料制造；农林废物资源化无害化利用技术研发；生物有机肥料研发；新材料技术研发；生物基 材料技术研发；资源循环利用服务技术咨询；防洪除涝设施管理；工程管理服务；农业面源和重金属污 染防治技术服务；生态恢复及生态保护服务；环保咨询服务；土壤环境污染防治服务；新材料技术推广 服务；水污染治理；园林绿化工程施工；土石方工程施工；土壤与肥料的复混加工；建筑材料销售；生 态环境材料销售；金属材料销售；肥料销售；化肥销售；生物基材料销售。（除依法须经批准的项目 外，凭营业执照依法自主开展经营活动）许可项目：建设工程施工；河道疏浚施工专业作业；建筑劳务 分包。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文 件或许可证件为准）。 ...

Core Insights - Nuo Wei Biotechnology (Wuxi) Co., Ltd. has recently completed a B+ round of financing, raising several tens of millions of RMB, with investors including Tianjin Botong Venture Capital and Xichuang Investment [1] Company Overview - Nuo Wei Biotechnology was established in 2023 and is located in Wuxi City, focusing primarily on research and experimental development [1] - The company has a registered capital of 15.09968216 million RMB and has completed its B+ round financing by 2025, with the transaction amount being several tens of millions of RMB [1] Investment and Intellectual Property - Nuo Wei Biotechnology has made investments in 2 external companies and holds 12 patent registrations [1] - The company possesses 2 administrative licenses [1] Shareholders - The shareholders of Nuo Wei Biotechnology include Wang Xiaofang, Beijing Nuo Wei Biotechnology Partnership (Limited Partnership), Beijing Guoxin Haixiang Equity Investment Partnership (Limited Partnership), Beijing Nuo Wei Technology Development Partnership (Limited Partnership), and Beijing Xingzhiyuan Technology Partnership (Limited Partnership) [1]

Group 1 - MIRXES-B (02629.HK) plans to globally offer 46.62 million shares, with 4.662 million shares available in Hong Kong and 41.958 million shares for international offering [1] - The subscription period is from May 15 to May 20, with a maximum offer price of HKD 23.30 per share and an entry fee of approximately HKD 2,353.49 for 100 shares [1] - The total expected fundraising amount is HKD 1.086 billion, with a net amount of HKD 881 million, intended for the development, regulatory filing, production, and commercialization of the core product GASTROClearTM [1] Group 2 - The company aims to enhance its "end-to-end" capabilities to capture significant commercial potential within the value chain and to fund ongoing and planned research and development [1] - Key cornerstone investors include Beijing Xunrui Enterprise Management Partnership (Limited Partnership) and Evergreen Gate Limited, which will subscribe to approximately 19.287 million shares at the offer price [1] - MIRXES-B is expected to be listed on the main board on May 23, 2025, with China International Capital Corporation Hong Kong Securities Limited and Jianyin International Financial Limited serving as joint sponsors [1] Group 3 - The company reported net profits of -56.6416 million USD, -69.2250 million USD, and -92.3270 million USD for the years ending December 31, 2022, 2023, and 2024, respectively, with year-on-year changes of -1738.36%, -22.22%, and -33.37% [2]